Moderna Stock Is Rising After an Upgrade. This Analyst Says It’s Time to Buy.

Moderna stock was climbing in premarket trading Friday after an analyst at Piper Sandler upgraded the shares and said the current price level was an attractive entry point.

Edward Tenthoff upgraded Moderna (ticker: MRNA) stock to Overweight from Neutral but left the target price unchanged at $445, implying a near 31% upside to the shares. Piper Sandler had downgraded the shares to neutral on Aug. 6.


Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button